RAPT Therapeutics, Inc. — Director's Dealing 2019

Oct 31, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: RAPT Therapeutics, Inc. (RAPT)
CIK: 0001673772
Period of Report: 2019-10-30

Reporting Person: Wong Brian Russell (Director, President and CEO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	100000	Direct
Common Stock	330000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (25000)		Indirect
Stock Option (right to buy)	$6.18	2028-03-27	Common Stock (200000)		Direct
Stock Option (right to buy)	$6.30	2029-03-27	Common Stock (66666)		Direct

Footnotes

F1: The number of shares of common stock reflects a 1-for-6 reverse stock split, which became effective July 19, 2019.

F2: The shares are held directly by The Wong Family Trust Dated February 4, 2008 for which the Reporting Person is a trustee.

F3: Each share of Series B Preferred Stock is convertible into approximately 0.166 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019). Shares of Series B Preferred Stock have no expiration date and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock, for no additional consideration.

F4: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.